Technologies for the detection of minimal residual disease (MRD) in leukemia and our understanding of the prognostic implications of MRD at different phases of treatment have significantly improved over the past decade. As a result, definitions of treatment failure based on bone marrow morphology by light microscopy are becoming increasingly inadequate for clinical care and trial design. In addition, novel therapies that may have increased efficacy and decreased toxicity in the setting of MRD compared to overt disease are changing clinical practice and challenging investigators to redefine treatment failure, the role of disease surveillance in remission, and clinical trial eligibility in the era of MRD.
18 March 2026 in Cancer Epidemiology, Biomarkers & Prevention
Background: Pediatric acute lymphoblastic leukemia (ALL) is the most common cancer in children, and its incidence and outcomes vary by race and ethnicity. Methods: The Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium has assembled a cohort of patients <25 years at diagnosis to examine genetic and neighborhood-level factors influencing ALL. As the cohort is ongoing, for this report, we examined sociodemographic and cytogenetic factors that might be associated with ALL outcome disparities. Results: Among 2,512 patients diagnosed between 2005 and 2020, we observed distinct patterns of genetic ancestry and residential characteristics across self-reported race and ethnicity. Latino children, who comprised 55.3% of the cohort, had a mean Amerindigenous ancestry proportion of 50.9%, whereas non-Latino White children exhibited a predominantly European ancestry (mean = 78%). Neighborhood-level analysis revealed significant socioeconomic and geographic differences by race/ethnicity, with Latino children more frequently residing in Latino enclaves or economically disadvantaged neighborhoods. Cytogenetic profiling of 551 patients showed that favorable subtypes (double trisomies and ETV6::RUNX1) predominated overall, but ETV6::RUNX1 was significantly less common in Latino than in non-Latino White children; conversely, CRLF2 overexpression and immunoglobulin heavy chain (IGH) rearrangements were more frequent among Latino children. Conclusions: This first REDIAL cohort analysis reveals how genetic ancestry and neighborhood-level factors jointly shape the distribution of ALL cytogenetic subtypes, advancing our understanding of contributors to disparities in ALL outcomes. Impact: This analysis offers insights into factors underlying disparities in ALL outcomes that may be targeted for mitigation, ultimately guiding more equitable approaches to risk stratification and intervention.
Background: Hepatotoxicity is a common treatment‐related complication in pediatric acute lymphoblastic leukemia (ALL). Excess adiposity at diagnosis has been identified as a risk factor, but the impact of weight change during therapy has not been examined. Methods: We included patients aged 2–20 years newly diagnosed with ALL between 2005 and 2021. Hepatotoxicity was defined as: (1) transaminitis (ALT/AST > 10× the upper limit of normal), or (2) conjugated hyperbilirubinemia (cbili; > 3.0 mg/dL during induction/> 2.0 mg/dL post‐induction). Youden's J was used to identify optimal BMI z‐score thresholds. Cox proportional hazards regression was used to assess associations between hepatotoxicity during treatment and diagnostic BMI and post‐induction hepatotoxicity and weight change during induction. Associations were adjusted for age, race, ethnicity, and treatment risk stratification. Patients were censored at qualifying event or 1200 days post‐diagnosis. Results: Among 1070 patients (median age 6 years), 45.8% developed transaminitis and 7.6% cbili. Optimal BMI z‐score cut points were −1.5 and 1.5 for transaminitis and 1.5 for cbili. A BMI z‐score ≤ −1.5 was associated with reduced transaminitis (HR = 0.58, 95% CI: 0.39–0.86; p = 0.006), while a z‐score ≥ 1.5 was associated with increased transaminitis (HR = 1.32, 95% CI: 1.06–1.65; p = 0.01). A BMI z‐score ≥ 1.5 was also associated with increased cbili (HR = 1.97, 95% CI: 1.23–3.18; p = 0.01). Weight change was not associated with transaminitis, but weight loss during induction was associated with an increase in hazard of post‐induction cbili (HR = 1.08, 95% CI: 1.04–1.11; p < 0.0001). Conclusion: Diagnostic BMI z‐score and weight loss during induction were associated with increased hepatotoxicity risk, highlighting potential targets for improved risk stratification and hepatoprotective interventions.
Background: In acute lymphoblastic leukemia (ALL), minimal residual disease (MRD) is an established biomarker of treatment response and strongly associated with poor outcomes. Among children with ALL, air pollution has been associated with lower survival but has not been evaluated with prognostic biomarkers such as end of induction (EOI) MRD. Methods: Using the Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium, we analyzed 2125 pediatric patients with ALL. Daily fine particulate matter (PM2.5) estimates were obtained from the Centers for Disease Control and Prevention and linked to patients’ residential and treatment center census tracts. Mean daily PM2.5 during induction was calculated using two definitions: (1) based solely on patients’ residential address, and (2) Days 1 to 7 based on the treatment center and Days 8 to EOI on patients’ residence. Patients were categorized in quartiles based on mean daily PM2.5. EOI MRD ≥0.1% or ≥0.01% was considered positive. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated using logistic regression. Results: In B-cell ALL (B-ALL), mean daily residential PM2.5 during induction was associated with positive EOI MRD in quartiles 2 (aOR: 1.56, 95% CI = 1.08 to 2.24) and 3 (aOR: 1.51, 95% CI = 1.05 to 2.17) but not quartile 4 (aOR: 1.19). The association across all 3 quartiles strengthened when restricted to National Cancer Institute (NCI) high-risk B-ALL (aOR range: 1.73-2.28). Conclusions: Residential PM2.5 was associated with positive EOI MRD in patients with NCI high-risk B-ALL. Our findings contribute to a growing body of evidence that environmental exposures are associated with inferior outcomes among children diagnosed with ALL.